Table 3.

Clinical and pathological features of the 142 gastric cancer patients and correlation with MSI status.

MSI (n = 23)			MSS (n = 119)
Features	Cases	Percentage%	Cases	Percentage%	p
Age					<0.0001
Mean	75.43		63.48
≤70	2	2.40%	81	97.60%
≥71	21	35.59%	38	64.41%
Sex					0.038
Male	10	11.20%	79	88.80%
Female	13	24.50%	40	75.50%
Location					0.015
Cardia	0	0.00%	23	100.00%
Fundus	0	0.00%	1	100.00%
Corpus	7	12.10%	51	89.70%
Antrum	16	27.10%	43	72.90%
Histological type					0.033
Intestinal	18	23.70%	58	76.30%
Diffuse	4	7.00%	53	93.00%
Mixed	1	11.10%	8	88.90%
Pathological diagnosis					0.324
Adenocarcinoma	21	20.20%	83	79.80%
Signet ring cell carcinoma	2	5.90%	32	94.10%
Small cell carcinoma	0	0.00%	2	100.00%
Undifferentiated carcinoma	0	0.00%	1	100.00%
Squamous cell carcinoma	0	0.00%	1	100.00%
Degree of differentiation					0.122
G1	6	33.30%	12	66.70%
G2	6	13.00%	40	87.00%
G3	11	14.90%	63	85.10%
T					0.593
Tis	2	33.30%	4	66.70%
T1a/T1b	2	13.30%	13	86.70%
T2	5	23.80%	16	76.20%
T3	7	12.30%	50	87.70%
T4a/T4b	7	16.27%	36	83.73%
N					0.647
N0	11	20.40%	43	79.60%
N1	4	10.50%	34	89.50%
N2	4	17.40%	19	82.60%
N3a/N3b	4	14.80%	23	85.20%
M					0.383
M0	22	17.10%	107	82.90%
M1	1	7.70%	12	92.30%
Stage					0.555
IA/IB	5	15.20%	28	84.80%
IIA/IIB	10	21.30%	37	78.72%
IIIA/IIIB/IIIC	7	15.20%	39	84.80%
IV	1	6.30%	15	93.70%
Lymphatic involvement				0.532
Yes	9	14.10%	55	85.90%
No	14	17.90%	64	82.10%
Vascular involvement				0.797
Yes	9	15.30%	50	84.70%
No	14	16.90%	69	83.10%
Perineural involvement				0.914
Yes	8	16.70%	40	83.30%
No	15	16.00%	79	84.00%
Adjuvant chemotherapy				0.33
Yes	5	11.60%	38	88.40%
No	18	18.20%	81	81.80%
Survival				0.618
Living	8	14.30%	48	85.70%
Deceased	15	17.40%	71	82.60%

MSI: Microsatellite instability; MSS: Microsatellite stability.